Trials / Completed
CompletedNCT01738373
Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation
Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 262 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Plerixafor | Plerixafor will be prescribed independently by the physician, according to usual practice. |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2012-11-30
- Last updated
- 2015-03-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01738373. Inclusion in this directory is not an endorsement.